← Leaderboards
Jiaoti Huang
Duke University
$7,876,254
Attributed
$11,903,684
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,903,684 · 8
By mechanism
R01$11,903,684 · 8
Top collaborators
- Steven K Clinton6 shared
- Chenglong Li6 shared
- Qianben Wang6 shared
- Chang-Deng Hu5 shared
- Xuesen Dong2 shared
- Wei Li1 shared
- Yang Yang1 shared
Most similar at Duke University
Same institution · by research overlap
- Redford B Williams$23,495,063
- Andrada Delia Neacsiu$2,256,194
- Xuesen Dong$433,829
- Jeffrey Petrella$224,999
- Daniel Edward Frigo$4,243,921
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateTumorAndrogen ReceptorMalignant NeoplasmsCessation Of LifeSamplingCellsImmunohistochemistryProstate Cancer CellResistanceAdenocarcinomaNeuroendocrine CarcinomaCancer EtiologyGenesTechnologyHistologicBiological MarkersBiopsyOncogenesMolecularAbirateroneCancer CellAndrogensHormone Therapy
Grant awards (31)
Elucidating alternative polyadenylation regulation during prostate cancer progression to castration-resistance$653,723
R01 · FY2025 · CA · contact PI
Targeting Undruggable Transcription Factor HoxB13 to Inhibit Prostate Cancer Metastasis$636,289
R01 · FY2025 · CA · contact PI
The role of focal adhesion kinase in therapy resistant prostate tumors$437,132
R01 · FY2025 · CA · contact PI
Glutaminase I isoforms as personalized biomarkers of prostate cancer$272,000
R01 · FY2025 · CA · contact PI
The role of focal adhesion kinase in therapy resistant prostate tumors$415,276
R01 · FY2024 · CA · contact PI
Glutaminase I isoforms as personalized biomarkers of prostate cancer$382,809
R01 · FY2024 · CA · contact PI
The role of focal adhesion kinase in therapy resistant prostate tumors$452,382
R01 · FY2023 · CA · contact PI
Glutaminase I isoforms as personalized biomarkers of prostate cancer$394,897
R01 · FY2023 · CA · contact PI
Glutaminase I isoforms as personalized biomarkers of prostate cancer$402,956
R01 · FY2022 · CA · contact PI
Role and targeting of PRMT5 in prostate cancer$504,707
R01 · FY2021 · CA
Role of oncogenic phosphorylated MED1 in aggressive prostate cancer$413,691
R01 · FY2021 · CA
Role and targeting of PRMT5 in prostate cancer$375,488
R01 · FY2021 · CA
Role and targeting of PRMT5 in prostate cancer$508,108
R01 · FY2020 · CA
Role of oncogenic phosphorylated MED1 in aggressive prostate cancer$383,629
R01 · FY2020 · CA
Histologic and Immunohistochemical Biomarkers for Heavily Treated Metastatic Prostate Cancer.$271,066
R01 · FY2020 · CA · contact PI
Role and targeting of PRMT5 in prostate cancer$497,903
R01 · FY2019 · CA
Role of oncogenic phosphorylated MED1 in aggressive prostate cancer$372,120
R01 · FY2019 · CA
Histologic and Immunohistochemical Biomarkers for Heavily Treated Metastatic Prostate Cancer.$262,933
R01 · FY2019 · CA · contact PI
Role and targeting of PRMT5 in prostate cancer$516,741
R01 · FY2018 · CA
Role of oncogenic phosphorylated MED1 in aggressive prostate cancer$386,836
R01 · FY2018 · CA
Histologic and Immunohistochemical Biomarkers for Heavily Treated Metastatic Prostate Cancer.$271,066
R01 · FY2018 · CA · contact PI
Role and targeting of PRMT5 in prostate cancer$547,569
R01 · FY2017 · CA
Role of oncogenic phosphorylated MED1 in aggressive prostate cancer$340,403
R01 · FY2017 · CA
A novel strategy to identify prostate cancer biomarkers for patient management$329,925
R01 · FY2017 · CA · contact PI
Histologic and Immunohistochemical Biomarkers for Heavily Treated Metastatic Prostate Cancer.$271,066
R01 · FY2017 · CA · contact PI
Role of oncogenic phosphorylated MED1 in aggressive prostate cancer$52,914
R01 · FY2017 · CA
A novel strategy to identify prostate cancer biomarkers for patient management$329,925
R01 · FY2016 · CA · contact PI
Histologic and Immunohistochemical Biomarkers for Heavily Treated Metastatic Prostate Cancer.$271,066
R01 · FY2016 · CA · contact PI
A novel strategy to identify prostate cancer biomarkers for patient management$319,550
R01 · FY2015 · CA · contact PI
A novel strategy to identify prostate cancer biomarkers for patient management$309,964
R01 · FY2014 · CA · contact PI
A novel strategy to identify prostate cancer biomarkers for patient management$319,550
R01 · FY2013 · CA · contact PI